SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00011258

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Paraoxonase and LDL Oxidation in Carotid Artery Disease

Atherosclerosis of the carotid arteries is a common cause of stroke. The prevalence and progression of carotid atherosclerosis are believed to be influenced by genetically inherited variations in lipoprotein metabolism. This study investigates the specific role of paraoxonase, an enzyme thought to detoxify atherogenic oxidized low-density lipoprotein. This study compares veterans who have significant carotid atherosclerosis on ultrasound examination with controls without carotid atherosclerosis. Both paraoxonase activity and genotype will be determined and compared between groups. The results may eventually make it possible to screen for a paraoxonase allele that confers high risk of atherosclerosis, and to diminish the risk by early treatment.

NCT00011258 Carotid Stenosis
MeSH: Carotid Stenosis Carotid Artery Diseases
HPO: Carotid artery stenosis

1 Interventions

Name: Paraoxonase

Type: Drug



There are 2 SNPs

SNPs


1 L55M

Two paraoxonase (PON1) polymorphisms, PON1-Q192R and PON1-L55M have been inconsistently associated with vascular disease. --- Q192R --- --- L55M ---


2 Q192R

Two paraoxonase (PON1) polymorphisms, PON1-Q192R and PON1-L55M have been inconsistently associated with vascular disease. --- Q192R ---



HPO Nodes


HPO:
Carotid artery stenosis
Genes 4
LMNA YY1AP1 ZMPSTE24 ABCA1